Eli Lilly has unveiled a $2.5 billion deal to acquire rights to a cancer therapy being developed by Scorpion Therapeutics in ...

After selling its PI3Kα program to Eli Lilly, Scorpion will spinout out a different entity, which will be owned by the ...

Despite these differences, the authors found that chemotaxis and electrotaxis share a dependence on similar intracellular signaling molecules, most notably the phosphoinositide 3-kinase (PI3K ...